Foley Hoag Represents Ginkgo Bioworks in Collaboration with Novo Nordisk

June 14, 2022

Foley Hoag LLP represented Ginkgo Bioworks, Inc. (NYSE: DNA), the leading horizontal platform for cell programming, in closing a collaboration agreement with Novo Nordisk A/S (NYSE: NVO) to create novel expression hosts for pharmaceutical products. Using synthetic biology, Ginkgo and Novo Nordisk will collaborate to unlock the potential of expression systems, which may accelerate and enhance the discovery and development of Novo Nordisk's biological medicines.

Under the terms of the partnership, Ginkgo and Novo Nordisk will launch a multi-year collaboration. Ginkgo will receive an upfront R&D fee and is eligible to receive milestone payments as the parties advance in the collaboration.

Ginkgo is building a platform to make programming cells as easy as programming computers. The company’s platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo is also actively supporting a number of COVID-19 response efforts, including K-12 pooled testing, vaccine manufacturing optimization and therapeutics discovery.

Foley Hoag attorneys Sarah Cooleybeck and Mark Potash represented Ginkgo in the transaction, with assistance from Nicola Lemay, William Gray and Ivanna Bihun.